Wuxi XDC (02268) announces a delightful profit, with expected annual net profit to increase by over 260% year-on-year.

Wuxi XDC (02268) announced that it expects its revenue, net profit, and adjusted net profit for the financial year ending December 31, 2024 to increase by over 85%, 260%, and 170% respectively compared to the corresponding figures for the financial year ending December 31, 2023. The company believes that the expected growth is mainly due to the following factors: (1) The continued rapid development of the downstream customers' industry of antibody-drug conjugates (ADC) and other biologic conjugate drugs; (2) The group's leading position and unique competitive advantage in the industry; (3) Further improvement in the group's profit margin, mainly attributed to the high production capacity utilization of the group's production facilities, the further enhancement of the group's production capacity through the commissioning of new production lines, the improvement in operational efficiency, and the interest income generated from the group's cash financial management.